Skip to main content
Purple Biotech Ltd. logo

Purple Biotech Ltd. — Investor Relations & Filings

Ticker · PPBT ISIN · IL0007650166 TA Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2025-12-04 Regulatory Filings
Country IL Israel
Listing TA PPBT

About Purple Biotech Ltd.

https://purple-biotech.com/

Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.

Recent filings

Filing Released Lang Actions
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
Regulatory Filings Classification · 95% confidence The document is a short regulatory filing (under 5,000 characters) from the Israel Securities Authority (MAGNA system) that explicitly states 'Attached hereto is a report on...' followed by a file name (ea026840901-pr_purplebioDRAFT1_isa.pdf). This fits the 'Menu vs Meal' rule, where the document serves as an announcement of a report rather than the report itself. Therefore, it is classified as a Report Publication Announcement (RPA).
2025-12-04 English
Other Report or Announcement
Earnings Release Classification · 100% confidence The document is a Form 6-K filed with the SEC by Purple Biotech Ltd. It contains a press release (Exhibit 99.1) announcing the company's financial results for the third quarter of 2025, including key highlights, business updates, and financial tables. While it is filed as a 6-K, the content is a standard quarterly earnings release. According to the filing definitions, an initial announcement of quarterly financial results is classified as an Earnings Release (ER). Q3 2025
2025-11-16 English
Other Report or Announcement
Regulatory Filings Classification · 95% confidence The document is a short notification from Purple Biotech Ltd filed via the Israel Securities Authority (MAGNA system). It explicitly states 'Attached hereto is a report on...' followed by the title of the report regarding Q3 2025 results. Because the document is a brief announcement serving as a cover for an attached file rather than the full financial report itself, it falls under the 'Report Publication Announcement' category.
2025-11-16 English
The company's financial results for the third quarter 2025 were reported abroad
Regulatory Filings Classification · 95% confidence The document is a short notification from the TASE (Tel Aviv Stock Exchange) compliance unit informing members that Purple Biotech Ltd has released its Q3 2025 financial results abroad. It does not contain the financial report itself, but rather serves as a formal notice of the report's publication. Following the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement.
2025-11-16 English
Purple Biotech Achieves Manufacturing Milestone for IM1240, a TriSpecific Antibody from the CAPTN-3 Platform-PR
Regulatory Filings Classification · 100% confidence The document is a press release issued by Purple Biotech Ltd. announcing a manufacturing milestone for their IM1240 product candidate. It follows the standard format of a corporate press release, including a headline, summary bullets, quotes from management, and a boilerplate 'About' section. It does not constitute a formal financial report (like a 10-K or IR), nor is it a regulatory filing or a specific shareholder notice. As it is a general corporate announcement regarding operational progress, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate announcements.
2025-10-29 English
Purple Biotech Achieves Manufacturing Milestone for IM1240, a TriSpecific Antibody from the CAPTN-3 Platform-PR
Regulatory Filings Classification · 95% confidence The document is a short regulatory filing (under 2,100 characters) from Purple Biotech Ltd submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on...' followed by a title regarding a corporate development (IM1240 antibody milestone). Per the 'Menu vs Meal' rule, since this is a short announcement providing a link/attachment to a report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2025-10-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.